Nuvalent (NUVL) Shares Outstanding (Diluted Average) (2020 - 2026)
Nuvalent (NUVL) reported Shares Outstanding (Diluted Average) of $78.7 million for Q1 2026, up 9.86% on a YoY basis from $71.6 million in Q1 2025, and up 8.23% quarter-over-quarter from $72.7 million in Q4 2025.
Nuvalent (NUVL) Shares Outstanding (Diluted Average) (2020 - 2026) Analysis & Trends
Nuvalent has reported Shares Outstanding (Diluted Average) for 7 years, with the latest figure at $78.7 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 9.86% year-over-year to $78.7 million; the trailing twelve-month figure through Mar 2026 stood at $78.7 million (up 9.86% YoY), and the FY2025 full-year result was $72.7 million, up 9.45% from the prior year.
- Shares Outstanding (Diluted Average) for Q1 2026 stood at $78.7 million, up from $72.7 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $78.7 million in Q1 2026, with the low at $48.3 million in Q1 2022.
- Historically, Shares Outstanding (Diluted Average) has averaged $61.8 million across 5 years, with a median of $64.2 million in 2024.
- Annual changes were most pronounced in 2022 — Shares Outstanding (Diluted Average) jumped 1465.14% — and 2025, when it increased 9.45%.
- Nuvalent's Shares Outstanding (Diluted Average) stood at $49.7 million in 2022, then gained by 17.22% to $58.2 million in 2023, then gained by 14.06% to $66.4 million in 2024, then advanced by 9.45% to $72.7 million in 2025, then gained by 8.23% to $78.7 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $78.7 million (Q1 2026), $72.7 million (Q4 2025), and $72.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 92.44 Mn |
| 10 | Nuvalent | 9.70 Bn | 9.70 Bn | - | 78.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 78.67 Mn |
| Dec 31, 2025 | 72.69 Mn |
| Sep 30, 2025 | 72.14 Mn |
| Jun 30, 2025 | 71.84 Mn |
| Mar 31, 2025 | 71.61 Mn |
| Dec 31, 2024 | 66.41 Mn |
| Sep 30, 2024 | 64.81 Mn |
| Jun 30, 2024 | 64.61 Mn |
| Mar 31, 2024 | 64.15 Mn |
| Dec 31, 2023 | 58.22 Mn |
| Sep 30, 2023 | 56.89 Mn |
| Jun 30, 2023 | 56.87 Mn |
| Mar 31, 2023 | 56.70 Mn |
| Dec 31, 2022 | 49.67 Mn |
| Sep 30, 2022 | 48.34 Mn |
| Jun 30, 2022 | 48.30 Mn |
| Mar 31, 2022 | 48.28 Mn |
| Dec 31, 2021 | 21.78 Mn |
| Sep 30, 2021 | 12.86 Mn |
| Jun 30, 2021 | 3.11 Mn |